Tempest Therapeutics Reports 100% CR Rate for CAR-T Therapy TPST-2003 in Multiple Myeloma & POEMS Syndrome

summarizeSummary

Tempest Therapeutics announced highly positive clinical data for its lead CAR-T therapy, TPST-2003, showing a 100% complete response rate in CAR-T-naïve patients with relapsed/refractory multiple myeloma and POEMS syndrome, alongside a favorable safety profile.

check_boxKey Events

• Exceptional Clinical Efficacy

  TPST-2003 achieved a 100% complete response rate in all 15 CAR-T-naïve efficacy evaluable patients across two Phase 1 trials (REDEEM-1 for rrMM and POEMS-1 for POEMS syndrome).

• Favorable Safety Profile

  The REDEEM-1 trial demonstrated a favorable safety profile with no Grade > 3 Cytokine Release Syndrome (CRS) or Immune effector cell-associated neurotoxicity syndrome (ICANS).

• Potential Class-Leading PFS

  Median progression-free survival (PFS) was 23.1 months, including in patients with extramedullary disease (EMD), which compares favorably to approved BCMA CAR-T therapies.

• Regulatory Pathway & Funding

  Tempest plans to meet with the FDA to discuss initiating a U.S. registrational study for TPST-2003 later this year, with all bolded development activities 100% funded by a strategic partner.

auto_awesomeAnalysis

This 8-K provides a significant clinical update for Tempest Therapeutics' lead CAR-T therapy, TPST-2003, which is critical for a company that recently disclosed a 'going concern' warning. The reported 100% complete response rate in CAR-T-naïve patients across two Phase 1 trials (REDEEM-1 and POEMS-1) for relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome is exceptionally strong. The favorable safety profile, with no Grade > 3 CRS or ICANS, further enhances the data. Notably, the median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease, potentially positions TPST-2003 as a class-leading therapy compared to existing approved treatments. The company's plan to discuss a U.S. registrational study with the FDA later this year, coupled with the disclosure that key development activities are 100% funded by a strategic partner, significantly de-risks the program and provides a clear path forward, directly addressing the financial concerns previously raised. This update represents a major positive catalyst for the company.